Genentech's Fenebrutinib Shows Unprecedented Positive Phase III Results as the Potential First and Only BTK Inhibitor in Both Relapsing and Primary Progressive Multiple Sclerosis

Core Insights - Genentech, a member of the Roche Group, announced that the first Phase III study (FENhance 2) for Fenebrutinib in patients with relapsing multiple sclerosis met its primary endpoint [1] Group 1: Study Results - The Phase III study demonstrated that Fenebrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, significantly reduced the annualized relapse rate (ARR) compared to teriflunomide [1]